U.S. markets closed

Inozyme Pharma, Inc. (INZY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.60-1.45 (-7.23%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close20.05
Open20.56
Bid18.60 x 1400
Ask20.77 x 800
Day's Range18.25 - 20.98
52 Week Range16.10 - 31.65
Volume38,519
Avg. Volume65,779
Market Cap436.432M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Inozyme Pharma Presents Data from Burden of Illness Study in Patients with ENPP1 Deficiency and ABCC6 Deficiency at the 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics
      GlobeNewswire

      Inozyme Pharma Presents Data from Burden of Illness Study in Patients with ENPP1 Deficiency and ABCC6 Deficiency at the 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics

      - Study results underscore high and shifting disease impacts across age groups, reflecting evolution of disease symptomology -BOSTON, April 14, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization disorders, today presented data that highlight the burden of disease for patients and families affected by ENPP1 Deficiency and ABCC6 Deficiency, two devastating and potentially deadly genetic diseases. In a poster entitled, From the Voice of Patients and Caregivers: Burden of Illness in Infantile Onset ABCC6 and ENPP1 Deficiency (GACI and ARHR2), Inozyme and GACI Global reported that patients in different age groups are impacted in different ways, an age-based shift that reflects the progression of these rare genetic diseases. The poster was presented virtually beginning on April 14th at the annual meeting of the American College of Medical Genetics and Genomics (ACMG). Patients with ENPP1 Deficiency or ABCC6 Deficiency exhibit a range of signs and symptoms that can include arterial calcification, cardiac and neurological involvement, skeletal abnormalities, and hearing loss. ENPP1 Deficiency manifests as generalized arterial calcification of infancy (GACI) type 1 in infants and autosomal recessive hypophosphatemic rickets type 2 (ARHR2) in children and adults. ABCC6 Deficiency is a disease that can lead to an acute form called GACI type 2 in infants and pseudoxanthoma elasticum (PXE) in older patients. “This study is the first to describe the burden of illness in infantile-onset ABCC6 Deficiency and across the age spectrum in patients with ENPP1 Deficiency,” noted Catherine Nester, Vice President of Physician and Patient Strategies at Inozyme, and one of the authors of the poster presented at ACMG. “Although we knew that the cardiovascular and skeletal complications of these diseases exact a significant burden on patients and families, we were surprised to learn just how burdensome the actual care coordination can be, from securing a diagnosis, to dealing with multiple tests and treatment options, to managing ongoing care from multiple specialists. The knowledge gained from this study will inform our efforts to develop therapies that we hope will ease the burden for patients and families living with these devastating rare genetic diseases.” Inozyme worked in partnership with GACI Global to conduct the From the Voice of Patients and Caregivers study. GACI Global is a patient advocacy organization dedicated to providing hope and education to patients and families affected by GACI and ARHR2. The study collected primary patient-reported outcomes data to determine the disease burden in individuals diagnosed with infantile-onset ABCC6 Deficiency or ENPP1 Deficiency in patients of all ages. A total of 38 respondents from nine countries participated in the study, including six individuals with ABCC6 Deficiency, 12 infants with ENPP1 Deficiency, 13 children with ENPP1 Deficiency, and seven adults with ENPP1 Deficiency. Parents or caregivers responded on behalf of patients younger than 18 years of age. The study included responses from parents or caregivers of 11 deceased patients, 10 of whom died within the first 12 months of life. The most frequently reported burdens for patients with ENPP1 Deficiency at all time points were: bone and joint pain (100% of adult patients, 85% of pediatric patients)cardiac issues (86% of adult patients, 85% of pediatric patients)mobility issues/fatigue (86% of adult patients, 85% of pediatric patients) The most frequently reported symptoms for patients with ABCC6 Deficiency were: gastrointestinal issues (83%)growth and development issues (83%)cardiac issues (67%) The study also assessed the importance of each burden for each cohort using a weighted score approach: In the ABCC6 Deficiency cohort, fear of the unknown was the heaviest burden, followed by cardiac issues and difficulty with the hospital experience.In the infant ENPP1 Deficiency cohort, cardiac issues were the greatest burden, followed by difficulty with the hospital experience and issues related to growth and development.In the pediatric ENPP1 Deficiency cohort, treatments/medications were most burdensome, followed by issues related to hearing loss and stress/anxiety.The adult ENPP1 Deficiency cohort was most burdened by issues related to bone/joint pain. Other heavily weighted burdens in this cohort included mobility issues, fatigue, and fear of the unknown. “From the unthinkable devastation of a new parent losing their child, to cardiac complications for infants, to the complex medical management of cardiovascular and skeletal issues in pediatric patients, and the cumulative impact of cardiovascular and skeletal complications in adults, this study clearly shows that ENPP1 and ABCC6 Deficiencies are chronic and highly morbid diseases that affect patients of all ages, as reflected in the constellation of physical, emotional, and social burdens across the age continuum,” commented Christine O’Brien, co-president of GACI Global and co-author of the study. “We hope our results spur further study of ABCC6 and ENPP1 Deficiencies, and that improved understanding, diagnosis, and management of these rare genetic diseases will alleviate some of the uncertainty and fear for patients and families.” About ENPP1 DeficiencyThe ENPP1 gene produces a critical enzyme called ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), which regulates inorganic pyrophosphate (PPi) levels in plasma. PPi is essential for preventing harmful soft tissue calcification and for regulating normal bone mineralization. ENPP1 Deficiency affects patients across the age spectrum and manifests as either generalized arterial calcification of infancy (GACI) type 1 or autosomal recessive hypophosphatemic rickets type 2 (ARHR2). GACI type 1 is a devastating and often fatal disease affecting infants and is characterized by calcification and narrowing of large and medium-sized arteries, resulting in heart failure and death in about half of patients within the first six months of life. Mutations in the ABCC6 gene can also cause an infantile onset of the disease called GACI type 2. ARHR2 manifests in the post-infancy stage and causes rickets, weakened bones, repeated bone fractures, skeletal deformities, short stature, muscle weakness, fatigue, and bone pain. About ABCC6 DeficiencyThe ABCC6 gene encodes a protein called ATP-binding cassette sub-family C member 6, a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across cellular membranes both within and outside of cells. ABCC6 Deficiency is a rare, inherited disorder caused by mutations in the ABCC6 gene, resulting in decreased or absent activity of the ABCC6 protein. A systemic and progressively debilitating condition estimated to affect more than 67,000 individuals worldwide, ABCC6 Deficiency leads to low levels of pyrophosphate (PPi) and is associated with pathological mineralization in blood vessels and soft tissues throughout the body. These effects can result in devastating medical problems including blindness, life-threatening cardiovascular complications, and skin calcification. Some infants with ABCC6 Deficiency are diagnosed with generalized arterial calcification of infancy (GACI) type 2, a vascular condition that resembles GACI type 1. In older patients, ABCC6 Deficiency presents as pseudoxanthoma elasticum (PXE), a rare, inherited disorder in which individuals develop calcification of soft connective tissues, including in the eyes, cardiovascular system, and skin. About INZ-701INZ-701 is an enzyme replacement therapy in development for the treatment of mineralization disorders of the circulatory system, bones, and kidneys. In preclinical studies, the experimental therapy has shown potential to generate plasma pyrophosphate (PPi) and to restore it to appropriate physiological levels, thereby preventing calcification in the vasculature and kidneys, while at the same time normalizing bone mineralization. Inozyme is developing INZ-701 for certain rare, life-threatening, and devastating genetic disorders such as ENPP1 Deficiency and ABCC6 Deficiency in which PPi levels are below the normal physiological levels. Inozyme is preparing to initiate a Phase 1/2 clinical trial in patients with ENPP1 Deficiency in the first half of 2021 and a separate Phase 1/2 clinical trial in patients with ABCC6 Deficiency in mid-2021. About Inozyme Pharma Inozyme Pharma (Nasdaq: INZY) is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com. About GACI GlobalGACI Global is a nonprofit patient advocacy group whose mission is to connect families affected by Generalized Arterial Calcification of Infancy of Hypophosphatemic Rickets caused by ENPP1 or ABCC6 deficiencies to each other and to the medical community. The organization strives to provide current educational resources and supports ongoing research. The goal of this 100% volunteer-run organization is to provide not only information about what complications can occur due to ENPP1 and ABCC6 deficiencies, but to provide hope for families impacted by the condition around the world. Cautionary Note Regarding Forward-Looking StatementsStatements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the initiation and timing of our future clinical trials, our research and development programs, the availability of preclinical study and clinical trial data, the timing of our regulatory applications and the period over which we believe that our existing cash, cash equivalents and investments will be sufficient to fund our operating expenses. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company’s ability to initiate its planned Phase 1/2 clinical trials of INZ-701 for ENPP1 Deficiency and ABCC6 Deficiency; obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in preclinical studies and clinical trials; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials; obtain, maintain and protect intellectual property rights related to its product candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties, and other important factors, in the Company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. ContactsInvestors:Inozyme PharmaAxel Bolte, co-founder, president, and chief executive officerir@inozyme.com Media:SmithSolveAlex Van Rees(973) 442-1555 ext. 111alex.vanrees@smithsolve.com

    • Inozyme Pharma to Present Burden of Illness Data at the 2021 ACMG Annual Clinical Genetics Meeting
      GlobeNewswire

      Inozyme Pharma to Present Burden of Illness Data at the 2021 ACMG Annual Clinical Genetics Meeting

      BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization, today announced that data from the burden of illness in infantile onset ABCC6 and ENPP1 deficiency study will be presented at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting taking place April 13-16, 2021. The following poster presentation will be available during the ACMG Annual Clinical Genetics Meeting beginning on Wednesday, April 14, 2021, at 7:00 a.m. ET: Title: From the Voice of Patients and Caregivers: Burden of Illness in Infantile Onset ABCC6 and ENPP1 Deficiency (GACI and ARHR2)Poster #: eP024 The poster will be accessible from the “Investors and Media” section of the Inozyme website at investors.inozyme.com following the conference. About Inozyme PharmaInozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy to treat ENPP1 and ABCC6 deficiencies. ENPP1 and ABCC6 deficiencies are chronic, systemic, and progressive diseases occurring over the course of a patient’s lifetime, starting as early as fetal development and spanning into adulthood. ENPP1 and ABCC6 deficiencies are estimated to occur in approximately one in 200,000 and one in 50,000 births, respectively. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com. Cautionary Note Regarding Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the initiation and timing of our future clinical trials and our research and development programs. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company’s ability to obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in preclinical studies and clinical trials; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials; obtain, maintain and protect intellectual property rights related to its product candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties, and other important factors, in the Company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. Contacts Investors:InozymeAxel Bolte, co-founder, president, and chief executive officer (857) 330-4345ir@inozyme.com Media:SmithSolveAlex Van Rees(973) 442-1555 ext. 111alex.vanrees@smithsolve.com

    • Inozyme Pharma Expands its Scientific Advisory Board
      GlobeNewswire

      Inozyme Pharma Expands its Scientific Advisory Board

      - Appoints veteran leaders with deep scientific and clinical expertise in vascular calcification, renal disease, and diseases with neointimal proliferation -BOSTON, April 01, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization, announced today changes to its scientific advisory board (SAB), including the addition of three leading key opinion leaders with specific expertise in the company’s lead indications: W Charles O’Neill IV, M.D., Director of the Ultrasonography Program in the Renal Division at Emory University School of MedicineJouni Uitto, M.D., Ph.D., Professor of Dermatology and Cutaneous Biology, and Biochemistry and Molecular Biology, and Chair of the Department of Dermatology and Cutaneous Biology at The Sidney Kimmel Medical College at Thomas Jefferson University, in Philadelphia, PennsylvaniaPaul B. Yu, M.D., Ph.D., Section Head of Cardiovascular Life Sciences at Brigham and Women’s Hospital and Associate Professor of Medicine at Harvard Medical School David Thompson, M.A., M.S., Ph.D., a senior adviser to Inozyme, who served as Inozyme’s Senior Vice President and Chief Scientific Officer from 2018-2020, will also be joining the SAB. Enrique M. De La Cruz, Ph.D., Jon S. Morrow, M.D., Ph.D., and Mark A. Lemmon, Ph.D. are stepping down from the SAB, effective immediately. “We are honored to welcome Charles, Jouni, and Paul, to Inozyme, and we are excited to have David accept this new role on our scientific advisory board. Their combined experience in ABCC6 deficiency, neointimal proliferation, and mineralization diseases with low pyrophosphate will be invaluable as we continue to explore the role of ENPP1 in new and intriguing indications,” said Yves Sabbagh, Ph.D., Senior Vice President and Chief Scientific Officer of Inozyme Pharma. “Inozyme is deeply thankful to Enrique, Jon, and Mark for their valuable advice and counsel through the early years.” W Charles O’Neill IV, M.D., is an accomplished physician-scientist in the Renal Division at Emory University School of Medicine where he leads an active basic and translational research program. His current research focuses on the pathophysiology of vascular calcification in renal failure, specifically examining the role of endogenous pyrophosphate in the etiology of vascular calcification. Jouni Uitto, M.D., Ph.D., is currently Professor of Dermatology and Cutaneous Biology, and Biochemistry and Molecular Biology, and Chair of the Department of Dermatology and Cutaneous Biology at The Sidney Kimmel Medical College at Thomas Jefferson University, in Philadelphia, Pennsylvania. He is also Director of the Jefferson Institute of Molecular Medicine at Thomas Jefferson University. Dr. Uitto is internationally recognized for his research on connective tissue biochemistry and molecular biology in relation to cutaneous diseases and skin aging with a special interest in Pseudoxanthoma Elasticum (PXE), also known as ABCC6 deficiency. Paul B. Yu, M.D., Ph.D., is a physician-scientist at Brigham and Women’s Hospital and an Associate Professor of medicine at Harvard Medical School. Dr. Yu’s clinical focus areas include cardiovascular disease, pulmonary vascular disease, and cardiovascular disease related to rheumatologic conditions. His research explores how signaling via the bone morphogenetic protein (BMP), activin, growth and differentiation factor (GDF), and TGF-beta signaling pathways regulate the consequences of injury and inflammation in cardiovascular, musculoskeletal, and metabolic diseases. The new and expanded SAB and the Clinical Advisory Board (CAB) of Inozyme is as follows: SAB: Yves Sabbagh, Ph.D., ChairInozyme Pharma (Senior Vice President and Chief Scientific Officer)Demetrios Braddock, M.D. Ph.D.Yale University School of MedicineCharles O’Neill, M.D.Emory University School of MedicineJoseph Schlessinger, Ph.D.Yale University School of MedicineEd Skolnik, M.D.New York University Langone Medical CenterRobert Terkeltaub, M.D.UC San Diego School of Medicine (UCSD)David Thompson, M.A., M.S., Ph.D.Inozyme Pharma (Senior Advisor)Jouni Uitto, M.D., Ph.D.The Sidney Kimmel Medical College at Thomas Jefferson UniversityPaul B. Yu, M.D., Ph.DBrigham and Women’s Hospital and Harvard Medical School CAB: Michael A. Levine, M.D., ChairThe Children's Hospital of Philadelphia (CHOP)Thomas O. Carpenter, M.D.Yale University School of MedicineFrank Rutsch, M.D.Münster University Children's Hospital About Inozyme PharmaInozyme Pharma, Inc. (Nasdaq: INZY), is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com. Cautionary Note Regarding Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the initiation and timing of our future clinical trials and our research and development programs. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company’s ability to obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in preclinical studies and clinical trials; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials; obtain, maintain and protect intellectual property rights related to its product candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties, and other important factors, in the Company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. ContactsInvestors:Inozyme PharmaAxel Bolte, co-founder, president, and chief executive officer ir@inozyme.com Media: SmithSolveAlex Van Rees(973) 442-1555 ext. 111alex.vanrees@smithsolve.com